Completed Phase 1 study of SCY-770, a first-in-class, highly selective, oral direct AMPK activator for the treatment of ADPKD; Phase 2 proof-of-concept trial to initiate in Q4 2026Awarded BARDA contract providing up to
JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the
Intravenous SCY-247 was generally well tolerated in healthy participants, with no drug-related serious adverse eventsOnce-daily intravenous doses of 50 mg or higher achieved exposures at or above the target identified
JERSEY CITY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS" or the "Company"), a clinical-stage biotechnology company dedicated to advancing innovative solutions for
• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated • Phase 2 proof-of-concept study in patients with ADPKD remains on-track to
BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health needNon-dilutive funding for
JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS" or the "Company"), a clinical-stage biotechnology company dedicated to advancing innovative solutions for
JERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare
JERSEY CITY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare
JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with
JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with
Initiated a Phase 1 study of SCY-770, a first-in-class, potent and direct AMPK activator for treatment of ADPKD; topline data are expected in Q3 2026 and are anticipated to inform dose selection for the planned Phase 2
JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1
JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS"), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today
Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)A Phase 2 proof-of-concept
